

TABLE 3 Risk factors for developing aGVHD grade III/IV

	No GVHD grade III/ IV	aGVHD grade III/ IV	Odds Ratio [95% CI]
<b>Gender</b>			
Male	95	8	1
Female	71	9	1.5 [0.5-4.7]
<b>Age</b>			
< 10 years of age	102	8	1
>= 10 years of age	64	9	1.8 [0.6-5.6]
<b>CMV Recipient</b>			
Positive	96	8	0.6 [0.2-1.9]
Negative	67	9	1
<b>Performance Score (Lansky/Karnofsky) at Transplant</b>			
80 or lower	32	3	0.9 [0.2-3.4]
≥90	129	14	1
<b>Cumulative Number of comorbidities</b>			
0 or 1	134	15	1
2 or more	31	2	0.6 [0.1-2.7]
<b>Graft Type</b>			
Bone marrow	114	14	1
Peripheral blood	17	1	0.5 [0-3.6]
Umbilical cord blood	32	2	0.5 [0.1 -2.4]
Other/combined sources	3	0	n/a
<b>Donor Type</b>			
Related	92	6	1
Unrelated	74	11	2.3 [0.7-7.8]
<b>Degree of HLA Match</b>			

Fully matched	113	7	1
Mismatched	47	10	3.4 [1.1-11.2]
<b>HLA Match/relation/source</b>			
Matched related donor	65	6	1
Matched Cord Blood (6/6)	13	0	0 [0-4.8]
Matched unrelated donor 8/8	35	1	0.3 [0-2.7]
Mismatched unrelated donor <8/8	8	8	10.4 [2.5-47.6]
Mismatched related donor 2 Ag	22	0	0 [0-2.7]
Mismatched cord blood (<6/6)	17	2	1.3 [0.1-8.0]
Missing	6	0	n/a
<b>Donor - Recipient SEX match</b>			
Female-Female or Male - Male	74	9	1
Female-Male or Male - Female	84	6	0.6 [0.2 -2.0]
<b>Donor – Recipient CMV Match</b>			
Negative-Negative or Positive - Positive	110	9	1
Negative –Positive or Positive - Negative	49	6	1.5 [0.4-5.0]
<b>Year of Transplant</b>			
2010 - 2012	43	5	1
2013 - 2015	52	9	1.5 [0.4-6.1]
2016 - 2019	71	3	0.4 [0.1-2.0]
<b>Conditioning Intensity</b>			
Myeloablative	91	10	1
Non-Myeloablative	34	4	1.1 [0.2-4.0]
Reduced Intensity	34	2	0.5 [0.1-2.7]
<b>Serotherapy</b>			
ATG	94	7	1

Alemtuzumab	55	8	1.9 [0.6-6.7]
Neither	15	2	1.8 [0.2-10.6]
<b>Rituximab used in conditioning</b>			
Yes	37	5	1.5 [0.4-5.0]
No	122	11	1